Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile

Journal of Medicinal Chemistry

Volumn 53, Issue 3, 2010, Pages 1397-1401

  Xue, Hai ^a   Lu, Xiaofan ^b   Zheng, Purong ^a   Liu, Li ^b   Han, Chunyan ^a   Hu, Jinping ^a   Liu, Zijie ^a   Ma, Tao ^a   Li, Yan ^a   Wang, Lin ^a   Chen, Zhiwei ^b   Liu, Gang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

10 CHLOROMETHYL 11 DEMETHYL 12 OXO CALANOLIDE A; 10,11 CYCLOPROPYL 12 OXO CALANOLIDE A; 6,6 DIMETHYL 10 CHLOROMETHYL 4 PROPYL 2H,6H,12H BENZO[ 1,2 B:3,4 B':5,6 B'']TRIPYRAN 2,12 DIONE; ANTIVIRUS AGENT; CALANOLIDE A; CYSTEINE; EFAVIRENZ; NEVIRAPINE; PYRAN DERIVATIVE; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG TOLERABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; BRAIN; CELL LINE; CELL SURVIVAL; HIV INFECTIONS; HIV-1; INHIBITORY CONCENTRATION 50; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; PYRANOCOUMARINS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 77249123906     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901653e     Document Type: Article

References (22)

1. Flexner, C. HIV drug development: the next 25 years. Nat. Rev. Drug Discovery 2007, 6, 959-966.
2. Drugs@FDA; http://www.accessdata.fda.gov/scripts/cder/drugsatfda.
3. Kashman, Y.; Gustafson, K. R.; Fuller, R. W.; Cardellina, J. H.; McMahon, J. B.; Currens, M. J.; Buckheit, R. W., Jr.; Hughes, S. H.; Cragg, G. M.; Boyd, M. R. HIV inhibitory natural products. Part 7. The calanolides, a novel HIV inhibitory class of coumarin derivatives from the tropical rainforest tree Calophyllumlanigerum. J. Med. Chem. 1992, 35, 2735-2743.
4. Currens, M. J.; Mariner, J. M.; McMahon, J. B.; Boyd, M. R. Kinetic Analysis of Inhibition of Human Immunodeficiency Virus Type-1 Reverse Transcriptase by Calanolide A. J. Pharmacol. Exp. Ther. 1996, 279, 652-661.
5. Currens, M. J.; Gulakowski, R. J.; Mariner, J. M.; Moran, R. A.; Buckheit, R. W., Jr.; Gustafson, K. R.; McMahon, J. B.; Boyd, M. R. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. J. Pharmacol. Exp. Ther. 1996, 279, 645-651.
6. Quan, Y.; Motakis, D.; Buckheit, R., Jr.; Xu, Z. Q.; Flavin, M. T.; Parniak, M. A.; Wainberg, M. A. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase. Antiviral Ther. 1999, 4, 203-209.
7. Buckheit, R. W., Jr.; Russell, J. D.; Xu, Z. Q.; Flavin, M. Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication. Antiviral Chem. Chemother. 2000, 11 (5), 321-327.
8. Auwerx, J.; Rodríguez-Barrios, F.; Ceccherini-Silberstein, F.; San-Félix, A.; Velázquez, S.; De, Clercq, E.; Camarasa, M. J.; Perno, C. F.; Gago, F.; Balzarini, J. The Role of Thr139 in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Sensitivity to (+)-CalanolideA.Mol. Pharmacol. 2005, 68, 652-659.
9. (a) Creagh, T.; Ruckle, J. L.; Tolbert, D. T.; Giltner, J.; Eiznhamer, D. A.; Dutta, B.; Flavin, M. T.; Xu, Z. Q. Safety and Pharmacokinetics of Single Doses of (1)-Calanolide A, a Novel, Naturally Occurring Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy, Human Immunodeficiency Virus-Negative Human Subjects. Antiviral Chem. Chemother. 2001, 45 (5), 1379-1386.
10. (b) Eiznhamer, D. A.; Creagh, T.; Ruckle, J. L.; Tolbert, D. T.; Giltner, J.; Dutta, B.; Flavin, M. T.; Jenta, T.; Xu, Z. Q. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. HIV Clin. Trials 2002, 3 (6), 435-450.
11. Sherer, R.; Dutta, B.; Anderson, R.; Laudette-Aboulhab, J.; Kamarulzaman, A.; D'Amico, R.; Paton, N.; Abdullah,M. S.; Pollard, R.;Cooley,T.; Flavin,M.T.; Xu,Z.Q.Aphase 1B study of (+)-calanolide A in HIV-1-infected, antiretroviral therapy-naive patients. 7th CROI, San Francisco, 2000, Abstract 508 .
12. 1. J. Med. Chem. 1997, 40, 1005-1017.
13. Xu, Z. Q.; Buckheit, R. W.; Stup, T. L.; Flavin, M. T.; Khilevich, A.; Rizzo, J. D.; Lin, L.; Zembower, D. E. In vitro anti-HIV activity of the chromanone derivatives, 12-oxo calanolide A, a novel NNRTI. Bioorg. Med. Chem. Lett. 1998, 8, 2179-2184.
14. Galinis, D. L.; Fuller, R. W.; McKee, T. C.; Cardellina, J. H., II; Gulakowski,R. J.;McMahon, J. B.; Boyd, M. R. Structure-Activity Modifications of the HIV-1 Inhibitors (+)-Calanolide A and (-)-Calanolide B. J. Med. Chem. 1996, 39, 4507-4510.
15. Sharma, G. V. M.; Ilangovan, A.; Narayanan, V. L.; Gurjar, M. K. First synthesis of aza-calanolides-a new class of anti-HIV active compounds. Tetrahedron 2003, 59, 95-99.
16. Sekino, E.; Kumamoto, T.; Tanaka, T.; Ikeda, T.; Ishikawa, T. Concise Synthesis of Anti-HIV-1 Active (+)-Inophyllum B and (+)-Calanolide A by Application of (-)-Quinine-Catalyzed Intramolecular Oxo-Michael Addition. J. Org. Chem. 2004, 69 (8), 2760-2767.
17. Ma, T; Liu, L; Xue, H; Li, L; Han, C. Y; Wang, L; Chen, Z. W; Liu, G. Chemical Library and Structure-Activity Relationships of 11-Demethyl-12-oxo- CalanolideAAnalogues asAnti-HIV-1Agents. J. Med. Chem. 2008, 51, 1432-1446.
18. Bourguignon, J. J.; Schoenfelder, A.; Schmitt, M.; Wermuth, C. G.; Hechler, V.; Charlier, B.; Maitre, M. Analogues of γ-Hydroxybutyric Acid. Synthesis and Binding Studies. J. Med. Chem. 1988, 31, 893-897.
19. Owen, L. N.; Sultanbawa, M. U. S. Olefinic acids. Part VI. α-Bromo-β-methoxycrotonic acid. J. Chem. Soc. 1949, 3105-3109.
20. Chen, Z. W; Zhou, P.; Ho, D. D.; Landau, N. R.; Marx, P. A. Genetically divergent strains of SIV use CCR5 as a coreceptor for entry. J. Virol. 1997, 71, 2075-2714.
21. Zhang, Z.; Hamatake, R.; Hong, Z. Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antiviral Chem. Chemother. 2004, 15, 121-134.
22. Fontaine, E.; Vaerenbergh,K. V.; Vandamme, A. M.; Schmit, J. C. Multidrug Resistant Human Immunodeficiency Virus Type 1. AIDS Rev. 1999, 1, 231-237.